BAL Pharma Consulting, Limited Liability Company
US and European, Private and Public Market Capitalization ranging from $50MM to $15Billion, VCs, Specialty Pharma, Pharma Commercial Service Organizations
European based private biotech client successfully out-licensed anti-bacterial receiving in excess of $20 million upfront payment from partner for a 1 year exclusive option to acquire U.S. rights to compound
BAL Pharma consulted to Client Management for 2+ years; developed Commercial Strategy, Valuation and Business case for partnering of asset
U.S. based private acute therapy start-up client successfully attained orphan status from the FDA for reformulated IV therapy
Through an extensive review of the scientific literature, BAL Pharma provided the documentation and estimated incidence of the orphan disease condition which was used to attain FDA orphan status; BAL Pharma generated a comprehensive forecase model to estimate the commercial potential of developing the IV therapy for treatment of the orphan disease condition
Public global specialty pharma client with market capitalization in excess of $10Billion invested in an extensive market development plan, including commercial and medical initiatives to raise awareness of unmet needs and prepare the market for commercialization of two oral products.
Led an analysis of "Best Practice" commercialization plans; Generated a comprehensive market development plan in excess of $5MM with metrics for Commercial & Medical Teams. The plan was executed.
Public U.S. biotech client with market capitalization of $250MM out-licensed development and commercialization rights of a phase 2 asset, realizing a significant upfront payment from the in-licenser.
With the Executive Management team, BAL Pharma developed a Business Plan for the phase 2 asset including commercial strategy, valuation, and licensing options. The business plan, a key component of the due diligence, was highly influential in convincing the partner to in-license worldwide rights to the phase 2 asset.
European based private biotech out-licensed phase 2 ulcerative colitis compound to a large public multi-national company receiving upfront payment, and a future royalty stream on based on achievement of development milestones and commercial revenue.